171 related articles for article (PubMed ID: 17642426)
1. Successful treatment of an invasive growth hormone-secreting pituitary macroadenoma in an 8-year-old boy.
Bowden SA; Sotos JF; Stratakis CA; Weil RJ
J Pediatr Endocrinol Metab; 2007 May; 20(5):643-7. PubMed ID: 17642426
[TBL] [Abstract][Full Text] [Related]
2. Cost of management of invasive growth hormone-secreting macroadenoma.
Luque-Ramírez M; Paramo C; Varela da Costa C; García-Mayor RV
J Endocrinol Invest; 2007; 30(7):541-5. PubMed ID: 17848835
[TBL] [Abstract][Full Text] [Related]
3. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
4. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Effects of Intracapsular Debulking and Adjuvant Somatostatin Analogs for Growth Hormone-Secreting Pituitary Macroadenoma: 10 Years of Experience in a Single Institute.
Shen SC; Shen CC; Pu TW; Cheng WY
World Neurosurg; 2019 Jun; 126():e41-e47. PubMed ID: 30716503
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report.
Waligórska-Stachura J; Gut P; Sawicka-Gutaj N; Liebert W; Gryczyńska M; Baszko-Błaszyk D; Blanco-Gangoo AR; Ruchała M
J Neurosurg; 2016 Aug; 125(2):346-9. PubMed ID: 26636388
[TBL] [Abstract][Full Text] [Related]
8. [Advances in the treatment of acromegaly].
Krysiak R; Okopień B; Marek B
Pol Merkur Lekarski; 2008 Jan; 24(139):59-65. PubMed ID: 18634256
[TBL] [Abstract][Full Text] [Related]
9. [Current diagnosis and treatment of acromegaly].
Melgar V; Espinosa E; Cuenca D; Valle V; Mercado M
Rev Med Inst Mex Seguro Soc; 2015; 53(1):74-83. PubMed ID: 25680646
[TBL] [Abstract][Full Text] [Related]
10. Inoperable Giant Growth Hormone-secreting Pituitary Adenoma: Radiological Aspects, Clinical Management and Pregnancy Outcome.
Dicuonzo F; Purciariello S; De Marco A; Guastamacchia E; Triggiani V
Endocr Metab Immune Disord Drug Targets; 2019; 19(2):214-220. PubMed ID: 30088454
[TBL] [Abstract][Full Text] [Related]
11. Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.
Oshino S; Saitoh Y; Kasayama S; Arita N; Ohnishi T; Kohara H; Izumoto S; Yoshimine T
Endocr J; 2006 Feb; 53(1):125-32. PubMed ID: 16543682
[TBL] [Abstract][Full Text] [Related]
12. Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration.
Ozbek M; Erdogan M; Akbal E; Gönülalan G
Exp Clin Endocrinol Diabetes; 2009 Jul; 117(7):309-11. PubMed ID: 18841538
[TBL] [Abstract][Full Text] [Related]
13. Acromegaly Presenting With Bilateral Vocal Fold Immobility: Case Report and Review of the Literature.
Cooper T; Dziegielewski PT; Singh P; Seemann R
J Voice; 2016 Nov; 30(6):758.e13-758.e16. PubMed ID: 26452616
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center.
Gheorghiu ML; Găloiu S; Vintilă M; Purice M; Hortopan D; Dumitraşcu A; Coculescu M; Poiană C
Hormones (Athens); 2016 Apr; 15(2):224-234. PubMed ID: 27376425
[TBL] [Abstract][Full Text] [Related]
15. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
[TBL] [Abstract][Full Text] [Related]
16. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S
PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977
[TBL] [Abstract][Full Text] [Related]
17. Colorectal neoplasm and acromegaly.
Bhansali A; Dutta P; Bhat MH; Sinha SK; Kochar R; Vaiphi K
Pituitary; 2006; 9(3):259-61. PubMed ID: 17072515
[TBL] [Abstract][Full Text] [Related]
18. Ectopic acromegaly due to a GH-secreting pituitary adenoma in the sphenoid sinus: a case report and review of the literature.
Ramírez C; Hernández-Ramirez LC; Espinosa-de-los-Monteros AL; Franco JM; Guinto G; Mercado M
BMC Res Notes; 2013 Oct; 6():411. PubMed ID: 24119925
[TBL] [Abstract][Full Text] [Related]
19. Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT/PCR is not associated with the pharmacological response to octreotide.
Gonzalez B; Vargas G; Ramirez C; Asa S; Cheng S; Sandoval C; Mercado M
Endocrinol Nutr; 2014 Dec; 61(10):523-30. PubMed ID: 25008035
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly.
Scaroni C; Albiger N; Daniele A; Dassie F; Romualdi C; Vazza G; Regazzo D; Ferraù F; Barresi V; Maffeis V; Gardiman MP; Cannavò S; Maffei P; Ceccato F; Losa M; Occhi G
J Clin Endocrinol Metab; 2019 Mar; 104(3):856-862. PubMed ID: 30285115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
